Compare EP & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EP | RANI |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.3M | 126.8M |
| IPO Year | 1996 | 2021 |
| Metric | EP | RANI |
|---|---|---|
| Price | $2.75 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 70.0K | ★ 768.0K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,203,000.00 | $1,633,000.00 |
| Revenue This Year | N/A | $274.77 |
| Revenue Next Year | N/A | $79.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $2.66 | $0.39 |
| 52 Week High | $5.80 | $3.87 |
| Indicator | EP | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 49.35 |
| Support Level | N/A | $0.83 |
| Resistance Level | $2.98 | $1.05 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 38.24 | 46.41 |
Empire Petroleum Corp is a conventional oil and natural gas producer with a main focus in the United States onshore. The company possesses long-life, mature, producing assets with slow decline profiles in the Permian Basin, Bakken region and central Gulf Coast region, in the states of New Mexico, North Dakota, Montana, Louisiana and Texas. It has production from operated and non-operated wells in Lea County in New Mexico, Bottineau, Renville, Burke, and McKenzie Counties in North Dakota, Richland County in Montana, St. Landry, Beauregard Parishes in Louisiana and Houston, Leon and Madison Counties in Texas.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.